Prove pharm
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Prove pharm sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Prove pharm: 3 sponsored US clinical trials, 2 recruiting.
Prove pharm sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ureter Injury, with 3 trials.
Upper-quartile sponsor footprint
Prove pharm sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment
NCT06085183
Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency
NCT06054880
3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
NCT04228445
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
Where Prove pharm enrollment is open (later-stage tilt)
2 recruiting of 3 indexed (67% open); 1 completed (33%).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Ureter Injury (3 trials), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Prove pharm: open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Prove pharm sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this Prove pharm page
3 registered trials is a research-attention snapshot, not an endorsement of Prove pharm or any single study.
- 2 of Prove pharm's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Ureter Injury is the condition Prove pharm studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ureter Injury trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Prove pharm pipeline card: 3 registered trials from official public datasets.Report a data error.